X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AEX-23, which targets OX1R and shows promise in modulating the effects of α-synuclein on neurons. Currently, it is being evaluated in the early-stage clinical trial studies for Parkinson's disease.
Lead Product(s): AEX-2
Therapeutic Area: Neurology Product Name: AEX-2
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Details:
The agreement grants NLS global rights to next-generation, oral, OX1R/OX2R agonists, including AEX-2, tailored to target narcolepsy, idiopathic hypersomnia, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, all of which involve cathepsins.
Lead Product(s): AEX-2
Therapeutic Area: Sleep Product Name: AEX-2
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Aexon Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2024
Details:
Under the agreement, NLS may acquire development and commercialization rights to Aexon Labs' dual orexin receptor agonists platform for the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Aexon Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 01, 2023
Details:
NLS-2 (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: NLS-2
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
Quilience (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
Quilience® (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Quilience® (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) which is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist which is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
Quilience® (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
Quilience (Mazindol ER), the Company's lead product candidate and proprietary extended-release formulation of Mazindol (Mazindol ER), is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypersomnia (IH).
Lead Product(s): Mazindol
Therapeutic Area: Psychiatry/Psychology Product Name: Nolazol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
